auto-fix: strip 4 broken wiki links

Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -19,22 +19,28 @@ The competitive dynamics (Lilly vs. Novo vs. generics post-2031) will drive pric
 
 
 ### Additional Evidence (extend)
-*Source: [[2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations]] | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5*
+*Source: 2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5*
 
 Real-world persistence data from 125,474 commercially insured patients shows the chronic use model fails not because patients choose indefinite use, but because most cannot sustain it: only 32.3% of non-diabetic obesity patients remain on GLP-1s at one year, dropping to approximately 15% at two years. This creates a paradox for payer economics—the "inflationary chronic use" concern assumes sustained adherence, but the actual problem is insufficient persistence. Under capitation, payers pay for 12 months of therapy ($2,940 at $245/month) for patients who discontinue and regain weight, capturing net cost with no downstream savings from avoided complications. The economics only work if adherence is sustained AND the payer captures downstream benefits—with 85% discontinuing by two years, the downstream cardiovascular and metabolic savings that justify the cost never materialize for most patients.
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-06-01-cell-med-glp1-societal-implications-obesity]] | Added: 2026-03-15*
+*Source: 2025-06-01-cell-med-glp1-societal-implications-obesity | Added: 2026-03-15*
 
 The Cell Press review characterizes GLP-1s as marking a 'system-level redefinition' of cardiometabolic management with 'ripple effects across healthcare costs, insurance models, food systems, long-term population health.' Obesity costs the US $400B+ annually, providing context for the scale of potential cost impact. The WHO issued conditional recommendations within 2 years of widespread adoption (December 2025), unusually fast for a major therapeutic category.
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-03-01-medicare-prior-authorization-glp1-near-universal]] | Added: 2026-03-15*
+*Source: 2025-03-01-medicare-prior-authorization-glp1-near-universal | Added: 2026-03-15*
 
 MA plans' near-universal prior authorization creates administrative friction that may worsen the already-poor adherence rates for GLP-1s. PA requirements ensure only T2D-diagnosed patients can access, effectively blocking obesity-only coverage despite FDA approval. This access restriction compounds the chronic-use economics challenge by adding administrative barriers on top of existing adherence problems.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16*
+
+Medicare-specific modeling shows $715M net savings over 10 years when comprehensive multi-indication access allows a single risk-bearing payer to capture cardiovascular ($1,512/subject), CKD ($2,074/subject), and T2D complication savings ($14,431/subject) that offset drug costs. This demonstrates the system-level vs. payer-level economics divergence: inflationary at the system level where costs and savings are distributed, but potentially cost-saving under capitated/risk-bearing arrangements.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md

@@ -32,10 +32,16 @@ For value-based care models and capitated payers, this multi-organ protection cr
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-12-23-jama-cardiology-select-hospitalization-analysis]] | Added: 2026-03-16*
+*Source: 2025-12-23-jama-cardiology-select-hospitalization-analysis | Added: 2026-03-16*
 
 SELECT trial exploratory analysis (N=17,604, median 41.8 months) shows semaglutide reduces ALL-CAUSE hospitalizations by 10% (18.3 vs 20.4 per 100 patient-years, P<.001) and total hospital days by 11% (157.2 vs 176.2 days per 100 patient-years, P=.01). Critically, benefits extended beyond cardiovascular causes to total hospitalization burden, suggesting systemic effects across multiple organ systems.
 
+
+### Additional Evidence (confirm)
+*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16*
+
+10-year Medicare modeling quantifies the multi-organ benefit: 38,950 cardiovascular events avoided (2,791 MIs, 3,000 revascularizations, 487 strokes per 100K subjects), plus CKD progression delay worth $2,074/subject and T2D complication avoidance worth $14,431/subject. The compounding effect is sufficient to produce net savings when a single payer captures all three benefit streams.
+
 ---
 
 Relevant Notes:

domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md

@@ -28,6 +28,12 @@ This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist,
 - FDA indication expansion to T2D patients with CKD (2024)
 - Dialysis cost benchmark: $90K+/year per patient
 
+
+### Additional Evidence (confirm)
+*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16*
+
+Medicare modeling confirms CKD savings of $2,074 per subject treated with semaglutide, contributing to overall net savings of $715M over 10 years. While T2D complication avoidance ($14,431/subject) produces larger per-patient savings, the CKD benefit is a meaningful component of the multi-indication value proposition.
+
 ---
 
 Relevant Notes:

inbox/archive/.extraction-debug/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.json

@@ -0,0 +1,24 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "comprehensive-glp-1-access-saves-medicare-money-when-single-payer-captures-multi-indication-benefits.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 1,
+    "kept": 0,
+    "fixed": 1,
+    "rejected": 1,
+    "fixes_applied": [
+      "comprehensive-glp-1-access-saves-medicare-money-when-single-payer-captures-multi-indication-benefits.md:set_created:2026-03-16"
+    ],
+    "rejections": [
+      "comprehensive-glp-1-access-saves-medicare-money-when-single-payer-captures-multi-indication-benefits.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-16"
+}

inbox/archive/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.md

@@ -7,9 +7,13 @@ date: 2025-06-01
 domain: health
 secondary_domains: [internet-finance]
 format: paper
-status: unprocessed
+status: enrichment
 priority: high
 tags: [glp-1, semaglutide, medicare, cost-effectiveness, cardiovascular, CKD, MASH]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -39,3 +43,13 @@ Key findings:
 PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
 WHY ARCHIVED: This study provides the strongest evidence that the "inflationary through 2035" framing needs scope qualification — system-level vs. payer-level economics diverge when downstream savings accrue to the same entity
 EXTRACTION HINT: Focus on the distinction between system-level cost impact (inflationary) and risk-bearing payer impact (potentially cost-saving). This is the core VBC interaction.
+
+
+## Key Facts
+- Medicare modeling projects 38,950 cardiovascular events avoided over 10 years with comprehensive semaglutide access
+- 6,180 deaths avoided (CV + CKD/MASH progression) in Medicare population over 10-year period
+- Per 100,000 subjects treated: 2,791 non-fatal MIs avoided, 3,000 coronary revascularizations avoided, 487 non-fatal strokes avoided, 115 CV deaths avoided
+- Average per-subject lifetime semaglutide treatment costs: $47,353
+- T2D-related Medicare savings: ~$892 million over 10 years
+- Obesity-related Medicare costs: ~$205 million over 10 years
+- MASH-related Medicare savings: ~$28 million over 10 years